{"id":51911,"date":"2022-12-13T14:02:35","date_gmt":"2022-12-13T13:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/"},"modified":"2022-12-13T14:02:35","modified_gmt":"2022-12-13T13:02:35","slug":"peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/","title":{"rendered":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury"},"content":{"rendered":"
\n

\n\u2013 Proceeds to advance lead program into clinical development\u2013<\/i>\n<\/p>\n

\n\u2013 Financing Led by Perceptive Xontogeny Venture Fund\u2013<\/i>\n<\/p>\n

PHILADELPHIA–(BUSINESS WIRE)–Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (\u201cPXV Fund\u201d). The company will use the proceeds to build upon the preclinical work conducted through collaborative partnership and seed investment with the Xontogeny development team to advance the lead candidate, PIP-2, through IND-enabling studies and into clinical development.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe data generated to date for PIP-2 represents a potential breakthrough in the prevention and treatment of ALI\u201d stated Thomas Han, Chief Executive Officer and Co-Founder of Peroxitech. \u201cWe are pleased with the progress we have made through the Xontogeny seed investment and to expand upon our close partnership through this PXV Fund Series A approval so that we can bring this compelling program forward to patients as expeditiously as possible.\u201d\n<\/p>\n

\nPeroxitech\u2019s lead asset mechanism leverages the discovery of a novel signaling pathway, NOX2, related to the oxidative injury cascade, which has demonstrated broad protection and rescue in several preclinical models. The Company\u2019s novel peptide shows it can protect cells from injury and enables injured ones to recover to near normal levels. These product characteristics could provide significant benefits in ALI and may have applications in other diseases.\n<\/p>\n

\n\u201cPeroxitech is well positioned with this unique mechanism, strong preclinical data, and a clear path forward to address the unmet needs in ALI\/ARDs and become a transformative treatment option for patients,\u201d said Chris Garabedian, Portfolio Manager of the PXV Funds, Chief Executive Officer of Xontogeny. \u201cPerceptive Advisors is excited to announce this investment to extend our support for Peroxitech as they progress through IND-enabling studies to accelerate the path to clinical development. We are confident in the program design and strategic pathway developed to provide meaningful clinical data in patients.\u201d\n<\/p>\n

\nPeroxitech was seeded and incubated at Xontogeny in 2021 to advance the program through confirmatory preclinical efficacy studies and further optimize the CMC development. In addition to the lead program, the company has also secured additional grants from the National Institutes of Health (NIH) for follow-on indications and further pipeline development. Peroxitech is led by Thomas Han and co-founded by Sheldon Feinstein, Ph.D. and Aron Fisher, M.D. Chris Garabedian and Ben Askew, Ph.D., Xontogeny Chief Executive Officer and Xontogeny Partner, Research and Development, respectively, serve on the Board of Directors.\n<\/p>\n

\nAbout Peroxitech<\/b>\n<\/p>\n

\nPeroxitech Inc. is a privately held biopharmaceutical company focused on the development and commercialization of a novel therapeutic for treatment of acute lung injury. The company was launched the University of Pennsylvania\u2019s Penn Center for Innovation (PCI) Ventures and was seeded at Xontogeny. In addition to the first clinical indication, Peroxitech is also evaluating our lead compound for several high unmet need areas where oxidative injury signaling pathways are a major contributor to disease progression.\n<\/p>\n

\nPlease visit our website for further information, www.peroxitech.com<\/a>\n<\/p>\n

\nAbout Perceptive Xontogeny Venture Fund<\/b>\n<\/p>\n

\nThe Perceptive Xontogeny Venture (PXV) Fund is Perceptive Advisors’ investment vehicle focused purely on early-stage, private venture investments in life sciences companies. Primary investments for the Fund include companies that are seeking a lead investor for Series A financings, which include both companies that are seeded and incubated at Xontogeny and companies that are seeded and incubated by other organizations, accelerators and investors. The PXV Fund is also open to participating in syndicated Series A financings as a co-lead or passive investor with other venture capital firms. For more information, visit www.perceptivelife.com<\/a>.\n<\/p>\n

\nAbout Xontogeny, LLC<\/b>\n<\/p>\n

\nBased in Boston, MA, Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with funding options as well as the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with founding scientists and entrepreneurs to support their vision while allowing a more efficient development model that benefits company founders and early equity holders. For more information visit www.xontogeny.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:<\/b>
Rachel Hutman
\n
Ford Hutman Media
\n
Rachel@fordhutmanmedia.com<\/a>
+1 301-801-5540\n<\/p>\n

\nInvestor Contact:<\/b>
Patrick Morrow, Director of Investor Relations & Marketing
\n
Perceptive Advisors
\n
patrick@perceptivelife.com<\/a>
+1 646-205-5344\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Proceeds to advance lead program into clinical development\u2013 \u2013 Financing Led by Perceptive Xontogeny Venture Fund\u2013 PHILADELPHIA–(BUSINESS WIRE)–Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (\u201cPXV … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51911","6":"format-standard","7":"category-industry"},"yoast_head":"\nPeroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Proceeds to advance lead program into clinical development\u2013 \u2013 Financing Led by Perceptive Xontogeny Venture Fund\u2013 PHILADELPHIA–(BUSINESS WIRE)–Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (\u201cPXV ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-13T13:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221213005315\/en\/1662785\/21\/peroxitech-color-logo-2-1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury\",\"datePublished\":\"2022-12-13T13:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005315\\\/en\\\/1662785\\\/21\\\/peroxitech-color-logo-2-1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/\",\"name\":\"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005315\\\/en\\\/1662785\\\/21\\\/peroxitech-color-logo-2-1.jpg\",\"datePublished\":\"2022-12-13T13:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005315\\\/en\\\/1662785\\\/21\\\/peroxitech-color-logo-2-1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005315\\\/en\\\/1662785\\\/21\\\/peroxitech-color-logo-2-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/","og_locale":"en_US","og_type":"article","og_title":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury - Pharma Trend","og_description":"\u2013 Proceeds to advance lead program into clinical development\u2013 \u2013 Financing Led by Perceptive Xontogeny Venture Fund\u2013 PHILADELPHIA–(BUSINESS WIRE)–Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (\u201cPXV ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-13T13:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221213005315\/en\/1662785\/21\/peroxitech-color-logo-2-1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury","datePublished":"2022-12-13T13:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/"},"wordCount":733,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005315\/en\/1662785\/21\/peroxitech-color-logo-2-1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/","url":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/","name":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005315\/en\/1662785\/21\/peroxitech-color-logo-2-1.jpg","datePublished":"2022-12-13T13:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221213005315\/en\/1662785\/21\/peroxitech-color-logo-2-1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221213005315\/en\/1662785\/21\/peroxitech-color-logo-2-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/peroxitech-announces-closing-of-25m-series-a-financing-to-develop-novel-treatment-for-acute-lung-injury\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51911"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51911\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}